Multidomain intervention

3 papers6 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funders: European Commission and 2 more

Human trial3

Outcomes

Physical function

upin humans2

2 studies

Multidomain intervention improves physical function in humans (between-group difference: +1.8 points, p = 0.001).
“participants receiving the intervention showed significant improvements in physical performance (SPPB: +1.6 points vs. + 0.3 in controls; between-group difference: +1.8 points, p = 0.001)”
Human trial6 monthsn = 90
Effects of a multidomain intervention on physical performance and sarcopenia in long-term care facility residents: The I-COUNT pilot randomized controlled trial
The journal of nutrition, health & aging13 Aug 2026
Multidomain intervention improves physical function in humans (p <0.05).
“Significant intervention effects were observed in mNTB primary outcomes including verbal memory (verbal paired associates), visual memory (visual paired associates), attention and working memory (digit span test), lower body flexibility (chair sit and reach), walking speed (6 meter walk test), cardiovascular endurance (2‐minute step test)”
Human trial(pre)-cognitive frailty2-yearsn = 106
The cost effectiveness of a multidomain intervention on physical, cognitive, vascular, dietary and psychosocial outcomes among community dwelling older adults with cognitive frailty in Malaysia: The AGELESS Trial
AAIC 2025 abstract23 Dec 2025

Sarcopenia

downin humans1

1 study

Multidomain intervention decreases sarcopenia in humans (37.1% to 15.4% vs 28.4% to 29.9%, p = 0.109).
“Sarcopenia prevalence decreased in the intervention group (37.1% to 15.4%) and remained stable in controls (28.4% to 29.9%), with a borderline group-by-time interaction (p = 0.109).”
Human trial6 monthsn = 90
Effects of a multidomain intervention on physical performance and sarcopenia in long-term care facility residents: The I-COUNT pilot randomized controlled trial
The journal of nutrition, health & aging13 Aug 2026